Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diamyd Medical's NP2 Enkephalin showed substantial and sustained reduction in a Phase I, open-label, dose escalation trial assessed as a potential therapy for chronic pain.
Subscribe to our email newsletter
Diamyd claims that NP2 Enkephalin is the first drug candidate from its proprietary NTDDS (Nerve Targeting Drug Delivery System)platform focally delivering therapeutic compounds directly to the nervous system.
The clinical trial report includes data from the four week observation period following one single administration of NP2, delivering Enkephalin, an opioid peptide, specifically to nerves experiencing pain from cancer.
The Phase I study is intended to test the safety of NP2 Enkephalin and the NTDDS platform. In addition to safety, measurements of pain relief and concomitant pain medications were collected.
Diamyd Medical US subsidiary Diamyd Inc CEO Darren Wolfe said that they are excited to report prolonged pain relief in this patient population with serious unmet medical need.
"It is gratifying for our entire team to have taken NP2 Enkephalin and the NTDDS platform from the bench to the bedside and report these encouraging results," Wolfe said.